{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:13:32Z","timestamp":1792620812790,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022449","name":"UNC Department of Obstetrics and Gynecology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Toxicology"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.crtox.2024.100149","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T07:37:58Z","timestamp":1704699478000},"page":"100149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Placental transfer of tofacitinib in the ex vivo dual-side human placenta perfusion model"],"prefix":"10.1016","volume":"6","author":[{"given":"Gaby A.M.","family":"Eliesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig","family":"van Hove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra H.H.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2599-7540","authenticated-orcid":false,"given":"Rick","family":"Greupink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.crtox.2024.100149_b0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0960-0760(91)90016-X","article-title":"Metabolism of prednisolone by the isolated perfused human placental lobule","volume":"39","author":"Addison","year":"1991","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.crtox.2024.100149_b0020","unstructured":"Anonymous. Eurocat register of congenital anomalies Northern Netherlands. June 2022 [cited 2023 15 March]; Available from: https:\/\/www.umcg.nl\/-\/eurocat\/jaarlijkse-cijfers."},{"issue":"6","key":"10.1016\/j.crtox.2024.100149_b0025","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1172\/JCI108236","article-title":"Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome","volume":"56","author":"Ballard","year":"1975","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.crtox.2024.100149_b0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/17425255.2016.1167187","article-title":"Use of anticancer agents in gynecological oncology during pregnancy: a systematic review of maternal pharmacokinetics and transplacental transfer","volume":"12","author":"Berveiller","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.crtox.2024.100149_b0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0002-9378(77)90466-5","article-title":"In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta","volume":"127","author":"Blanford","year":"1977","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.crtox.2024.100149_b0040","first-page":"1091","article-title":"Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure","volume":"20","author":"Broms","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.crtox.2024.100149_b0045","first-page":"1","article-title":"Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.crtox.2024.100149_b0050","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211018097","article-title":"The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU","volume":"14","author":"Chaparro","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"8","key":"10.1016\/j.crtox.2024.100149_b0055","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.crtox.2024.100149_b0060","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.2006.108324","article-title":"A meta-analysis on the influence of inflammatory bowel disease on pregnancy","volume":"56","author":"Cornish","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.crtox.2024.100149_b0065","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.rdc.2016.12.004","article-title":"Fertility, pregnancy, and lactation in rheumatoid arthritis","volume":"43","author":"de Jong","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"1","key":"10.1016\/j.crtox.2024.100149_b0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-021-02587-8","article-title":"Blocking Jak\/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis","volume":"23","author":"Di Benedetto","year":"2021","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.crtox.2024.100149_b0075","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfx063","article-title":"Editor's highlight: placentaldisposition and effects of crizotinib: an ex vivo study in the isolated dual-side perfused human cotyledon","volume":"157","author":"Eliesen","year":"2017","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.crtox.2024.100149_b0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cpt.1827","article-title":"Assessment of placental disposition of infliximab and etanercept in women with autoimmune diseases and in the ex vivo perfused placenta","volume":"108","author":"Eliesen","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.crtox.2024.100149_b0010","series-title":"Xeljanz Epar Public Assessment Report","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.crtox.2024.100149_b0015","series-title":"Xeljanz summary of product characteristics","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.crtox.2024.100149_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102320","article-title":"Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients","volume":"68","author":"Fernandez","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"issue":"17","key":"10.1016\/j.crtox.2024.100149_b0090","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/bdr2.1942","article-title":"Fetal exposure to tofacitinib during the first trimester: a healthy newborn case report","volume":"113","author":"Fernandez-Sanchez","year":"2021","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.crtox.2024.100149_b0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2018.04.017","article-title":"Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue","volume":"119","author":"Freriksen","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.crtox.2024.100149_b0100","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17512433.2018.1525293","article-title":"The use of biologics and small molecules in pregnant patients with rheumatic diseases","volume":"11","author":"Gerosa","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.crtox.2024.100149_b0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.crtox.2024.100149_b0110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5114\/ada.2020.96294","article-title":"The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation","volume":"37","author":"Goralczyk","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"issue":"5","key":"10.1016\/j.crtox.2024.100149_b0115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Gotestam Skorpen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.crtox.2024.100149_b0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/clpt.2011.66","article-title":"The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs","volume":"90","author":"Hutson","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.crtox.2024.100149_b0125","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/annonc\/mdv172","article-title":"Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model","volume":"26","author":"Jovelet","year":"2015","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.crtox.2024.100149_b0130","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1080\/14767058.2022.2128645","article-title":"Impact of chemotherapy during pregnancy on fetal growth","volume":"35","author":"Maggen","year":"2022","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"12","key":"10.1016\/j.crtox.2024.100149_b0135","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.crtox.2024.100149_b0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MIB.0000000000000596","article-title":"Use of immunomodulators and biologics before, during, and after pregnancy","volume":"22","author":"McConnell","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.crtox.2024.100149_b0145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fimmu.2020.00589","article-title":"What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis?","volume":"11","author":"Mehta","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.crtox.2024.100149_b0150","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","article-title":"Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Narula","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.crtox.2024.100149_b0155","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.repbio.2017.05.005","article-title":"Involvement of STAT1 in proliferation and invasiveness of trophoblastic cells","volume":"17","author":"Pereira de Sousa","year":"2017","journal-title":"Reprod. Biol."},{"key":"10.1016\/j.crtox.2024.100149_b0160","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.3389\/fimmu.2018.02597","article-title":"Regulation of placental extravillous trophoblasts by the maternal uterine environment","volume":"9","author":"Pollheimer","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crtox.2024.100149_b0165","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.placenta.2020.12.015","article-title":"Transfer of uremic solutes across the human term placenta: an ex vivo study in the dual-side perfused cotyledon","volume":"104","author":"Schakenraad","year":"2021","journal-title":"Placenta"},{"key":"10.1016\/j.crtox.2024.100149_b0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.placenta.2022.05.003","article-title":"Ex vivo dual perfusion of an isolated human placenta cotyledon: Towards protocol standardization and improved inter-centre comparability","volume":"126","author":"Schneider","year":"2022","journal-title":"Placenta"},{"issue":"2","key":"10.1016\/j.crtox.2024.100149_b0175","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1210\/jc.2017-02140","article-title":"Transfer and metabolism of cortisol by the isolated perfused human placenta","volume":"103","author":"Stirrat","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.crtox.2024.100149_b0180","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1242\/dev.163428","article-title":"Development of the human placenta","volume":"146","author":"Turco","year":"2019","journal-title":"Development"},{"key":"10.1016\/j.crtox.2024.100149_b0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.placenta.2022.03.128","article-title":"Placental transfer and vascular effects of pharmaceutical drugs in the human placenta ex vivo: a review","volume":"122","author":"van Hove","year":"2022","journal-title":"Placenta"},{"issue":"4","key":"10.1016\/j.crtox.2024.100149_b0190","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.crtox.2024.100149_b0195","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bcp.12642","article-title":"Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study","volume":"80","author":"Weber-Schoendorfer","year":"2015","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Current Research in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666027X24000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666027X24000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T17:19:34Z","timestamp":1718039974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666027X24000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":39,"alternative-id":["S2666027X24000021"],"URL":"https:\/\/doi.org\/10.1016\/j.crtox.2024.100149","relation":{},"ISSN":["2666-027X"],"issn-type":[{"value":"2666-027X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placental transfer of tofacitinib in the ex vivo dual-side human placenta perfusion model","name":"articletitle","label":"Article Title"},{"value":"Current Research in Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crtox.2024.100149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100149"}}